趋化因子来救援：白细胞介素-8 介导乳腺癌对 PI3K 通路靶向治疗的耐药性。
Chemokine to the rescue: interleukin-8 mediates resistance to PI3K-pathway-targeted therapy in breast cancer.
机构信息
Oncology Research, Pfizer Worldwide Research and Development, 10777 Science Center Drive, CB3/1376, San Diego, CA 92121, USA.
出版信息
Cancer Cell. 2012 Dec 11;22(6):703-5. doi: 10.1016/j.ccr.2012.11.012.
PMID:23238010
Abstract
Adaptive resistance to PI3K-mTOR inhibitors potentially limits the clinical antitumor activities of these agents. In this issue of Cancer Cell, Britschgi and coworkers show that certain tumors acquire resistance to PI3K-mTOR inhibitors through activation of a JAK2-dependent pathway, leading to interleukin-8 secretion.
摘要
对 PI3K-mTOR 抑制剂的适应性耐药可能会限制这些药物的临床抗肿瘤活性。在本期《癌细胞》杂志中，Britschgi 及其同事表明，某些肿瘤通过激活依赖 JAK2 的途径获得对 PI3K-mTOR 抑制剂的耐药性，从而导致白细胞介素-8 的分泌。
Zotero 插件